靶向双肿瘤相关抗原（tumor-associated antigen，TAA）的双抗ADC（bispecific ADC）具有多种潜在抗肿瘤优势：

1. 同时靶向双肿瘤驱动分子，克服耐药性；

2. 识别双TAA共表达的肿瘤细胞，增加靶向肿瘤特异性，降低脱靶毒性；

3. 双靶点组合产生新的内吞动力学机制，更高效的杀伤肿瘤。

基于RenLite平台的双抗ADC构建

百奥赛图双抗ADC平台优势

1. RenLite来源的共同轻链抗体易于构建双抗分子，且性质稳定易于后期开发，显著降低了CMC工艺开发难度
2. 靶点敲除（KO）小鼠免疫获得的抗体表位丰富，多物种交叉且物种间亲和力接近
3. 候选靶点多，多物种检测药效和毒性，开发周期短成功率高

基于RenLite的百奥赛图双抗ADC平台小视频

货架型TAA抗体骨架序列

20+在研双抗ADC，开放合作

资料下载

SITC 2023: *DM001, a novel TROP2xEGFR bsADC, demonstrates potent tumor growth inhibition in preclinical models and favorable safety profile in monkey

SITC 2023:Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1

SITC 2023: *DM005, an EGFR х MET bsADC with a novel DNA topoisomerase I inhibitor payload, showed robust anti-tumor activity in preclinical models

SITC 2023: BSA01, a bsADC targeting EGFR and membrane-bound MUC1-C, exhibits anti-tumor efficacy in vivo

SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types

SITC 2023: A novel bsADC targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity 

AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET 

AACR2023：Discovery of BCG033, A Novel Anti-PTK7xTROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer 

AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1 

AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate 

IO Summit EU 2023: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs 

AACR 2022：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy  

World ADC San Diego2022：YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 

PEGS EUROPE 2022：YH013, a fully-human EGFR x c-MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy